BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders
New preclinical data characterizing NE3107 mechanism of action featured in oral presentation Phamacokinetic data from…
New preclinical data characterizing NE3107 mechanism of action featured in oral presentation Phamacokinetic data from…
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company…
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company…
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions…
ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions…
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling…
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling…
Financing led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels Superluminal…
Financing led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels Superluminal…
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into…
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into…
Phase 2b trial of TOUR006 is expected to report top-line clinical data in the first…
Phase 2b trial of TOUR006 is expected to report top-line clinical data in the first…
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions…
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions…
WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage…